PMParis Astrid Mier-Maldonado

Paris Astrid Mier-Maldonado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paris Astrid Mier-Maldonado has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Step Forward in the Suitability of Silver Nanoparticle Properties for Nanomedicine Applications

    by Paris Astrid Mier-Maldonado, Edgar Ramiro Mendez-Sanchez, Nina Bogdanchikova, Juan Carlos García-Ramos, Yanis Toledano-Magaña, Luis Jesús Villarreal-Gómez, Antonio García-Anacleto, Roberto Luna Vázquez-Gómez, Lucia Engracia Azuara-Alvarez, María Evarista Arellano García, et al.

    Background/Objectives: Silver nanoparticles (AgNPs) hold great promise for antimicrobial, antiviral, and anticancer applications; however, concerns about their toxicity remain a major barrier to their medical use. This study systematically evaluates the acute oral toxicity of five well-characterized AgNP formulations from the Argovit™ family, which previously showed remarkable biomedical properties. Methods: We determine the median lethal dose (LD50), assess clinical signs, and identify the histopathological alterations in mice following oral administration for each formulation. The LD50 was calculated for AgNPs (metallic silver plus stabilizing agent) and for the complete formulation (including water). Results: All formulations showed exceptionally high LD50 values (86,020–150,535 mg/kg) considering the complete formulation, surpassing those reported for other AgNPs in the literature (typically ≤5,000 mg/kg). Clinical signs and toxicological assessment reveal differences in the response of the AgNPs formulations, but all exhibit extremely low toxicity. Histopathological changes were minimal compared to those caused by other AgNP formulations, even though we used doses several times higher. The estimated human LD50 values for the assessed Argovit AgNPs formulations are 17-30 times higher than those reported for other AgNP formulations in the literature. Conclusions: The remarkably low toxicity found in this work contradicts the prevailing assumption that only biogenically synthesized AgNP are biocompatible, highlighting these synthetic PVP-AgNP formulations as a highly safe alternative. The study suggests that the low LD50 may be due to the peculiar structure of Argovit AgNP formulations, which, according to recent data, consists of Ag cores incorporated into PVP nano- and microgels. A high percentage of rapid elimination of Argovit AgNPs from organisms (>98%) via feces also contributes to low LD50. To our knowledge, the present work is the first to study the LD50 of AgNPs-nanogel systems.

  • Open Access

    Antitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio

    by Omar Ulises Cruz-Ramírez, Lucía Margarita Valenzuela-Salas, Alberto Blanco-Salazar, José Antonio Rodríguez-Arenas, Paris A. Mier-Maldonado, Juan Carlos García-Ramos, Nina Bogdanchikova, Alexey Pestryakov, Yanis Toledano-Magaña

    Silver nanoparticles (AgNPs) not only have shown remarkable results as antimicrobial and antiviral agents but also as antitumor agents. This work reports the complete characterization of five polyvinylpyrrolidone-coated AgNP (PVP-AgNP) formulations, their cytotoxic activity against human colon tumor cells (HCT-15), their cytotoxic effect on primary mouse cultures, and their lethal dose on BALB/c mice. The evaluated AgNP formulations have a composition within the ranges Ag: 1.14–1.32% w/w, PVP: 19.6–24.5% and H2O: 74.2–79.2% with predominant spherical shape within an average size range of 16–30 nm according to transmission electron microscopy (TEM). All formulations assessed increase mitochondrial ROS concentration and induce apoptosis as the leading death pathway on HCT-15 cells. Except for AgNP1, the growth inhibition potency of AgNP formulations of human colon tumor cancer cells (HCT-15) is 34.5 times higher than carboplatin, one of the first-line chemotherapy agents. Nevertheless, 5–10% of necrotic events, even at the lower concentration evaluated, were observed. The cytotoxic selectivity was confirmed by evaluating the cytotoxic effect on aorta, spleen, heart, liver, and kidney primary cultures from BALB/c mice. Despite the cytotoxic effects observed in vitro, the lethal dose and histopathological analysis showed the low toxicity of these formulations (all of them on Category 4 of the Globally Harmonized System of Classification and Labelling of Chemicals) and minor damage observed on analyzed organs. The results provide an additional example of the rational design of safety nanomaterials with antitumor potency and urge further experiments to complete the preclinical studies for these AgNP formulations.


  • Open Access

    New Protein-Coated Silver Nanoparticles: Characterization, Antitumor and Amoebicidal Activity, Antiproliferative Selectivity, Genotoxicity, and Biocompatibility Evaluation

    by Lucía Margarita Valenzuela-Salas, Alberto Blanco-Salazar, Jesús David Perrusquía-Hernández, Mario Nequiz-Avendaño, Paris A. Mier-Maldonado, Balam Ruiz-Ruiz, Verónica Campos-Gallegos, María Evarista Arellano-García, Juan Carlos García-Ramos, Alexey Pestryakov, et al.

    Nanomaterials quickly evolve to produce safe and effective biomedical alternatives, mainly silver nanoparticles (AgNPs). The AgNPs’ antibacterial, antiviral, and antitumor properties convert them into a recurrent scaffold to produce new treatment options. This work reported the full characterization of a highly biocompatible protein-coated AgNPs formulation and their selective antitumor and amoebicidal activity. The protein-coated AgNPs formulation exhibits a half-inhibitory concentration (IC50) = 19.7 µM (2.3 µg/mL) that is almost 10 times more potent than carboplatin (first-line chemotherapeutic agent) to inhibit the proliferation of the highly aggressive human adenocarcinoma HCT-15. The main death pathway elicited by AgNPs on HCT-15 is apoptosis, which is probably stimulated by reactive oxygen species (ROS) overproduction on mitochondria. A concentration of 111 µM (600 µg/mL) of metallic silver contained in AgNPs produces neither cytotoxic nor genotoxic damage on human peripheral blood lymphocytes. Thus, the AgNPs formulation evaluated in this work improves both the antiproliferative potency on HCT-15 cultures and cytotoxic selectivity ten times more than carboplatin. A similar mechanism is suggested for the antiproliferative activity observed on HM1-IMSS trophozoites (IC50 = 69.2 µM; 7.4 µg/mL). There is no change in cell viability on mice primary cultures of brain, liver, spleen, and kidney exposed to an AgNPs concentration range from 5.5 µM to 5.5 mM (0.6 to 600 µg/mL). The lethal dose was determined following the OECD guideline 420 for Acute Oral Toxicity Assay, obtaining an LD50 = 2618 mg of Ag/Kg body weight. All mice survived the observational period; the histopathology and biochemical analysis show no differences compared with the negative control group. In summary, all results from toxicological evaluation suggest a Category 5 (practically nontoxic) of the Globally Harmonized System of Classification and Labelling of Chemicals for that protein-coated AgNPs after oral administration for a short period and urge the completion of its preclinical toxicological profile. These findings open new opportunities in the development of selective, safe, and effective AgNPs formulations for the treatment of cancer and parasitic diseases with a significant reduction of side effects.